Heading into 2024, the pharma industry finds itself in uncharted waters. On the one hand, the sector’s commitment to R&D investment and innovation output is likely to remain strong, with tools based on AI, automation and real-world data promising more streamlined drug candidate optimization. Additionally, the pharma sector is typically resilient in economic downturns. Financial…

The ever-evolving landscape of pharmaceutical regulations has long been challenging to navigate, but now pharma companies face additional complexities with the introduction of the Inflation Reduction Act (IRA) and the ongoing implementation of the 340B drug pricing program. In recent years, the IRA has made waves for its impact on the pharmaceutical industry, including proposals…

Embracing change management in pharmaceutical sales has become an essential competency for sales leaders. As a sales performance consultant who has worked with pharmaceutical and life sciences companies for over two decades, I’ve seen firsthand how the pace and frequency of change within pharma organizations has rapidly accelerated, making adaptation a constant requirement. Pharmaceutical sales…

Lilly has announced that Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire at the end of the year after 34 years with the company. The segment has been a key growth driver for the company and Lilly’s tirzepatide in particular has significant revenue growth potential.  Lilly’s foray into the…